Milestone Pharmaceuticals Inc.
Calcium channel antagonist for atrial arrhythmias
This article was originally published in Start Up
Executive Summary
Milestone Pharmaceuticals Inc. is developing a short-acting calcium channel blocker to treat a heart arrhythmia called paroxysmal supraventricular tachycardia. PSVT usually isn’t life-threatening and typically resolves on its own, but it is alarming and often leads patients to the emergency room. Milestone envisions that its drug will be used at home as episodes arise. It has a half-life of just one to four minutes and is delivered intranasally to get to the heart quickly.
You may also be interested in...
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart
Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.